Health and wellness products company USANA Health Sciences (NYSE:USNA) will be announcing earnings results this Tuesday after market close. Here’s what investors should know. USANA beat analysts’ ...

Holdings has accelerated revenue growth and expanded gross margins. Read what supports a compelling long-term investment ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of ...

Moderna Inc. research and ratings by Barron's. View MRNA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing ...

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025.

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader market significantly in Q2 2025. With a 12.12% weighting in the S&P 500, ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced.

Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...

Recent discussions on X about Moderna, Inc. (MRNA) have been buzzing with excitement following the company's announcement of positive late-stage trial results for its experimental mRNA-based ...

Moderna, Inc. (MRNA) announced Monday positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal ...